• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …

Aims The risk and incidence of cardiovascular (CV) immune-related adverse events (irAEs)
associated with immune checkpoint inhibitors (ICIs) in cancer patients remain unknown …

ESC Guidelines e341 (1) the specific situation of the patient. In this respect, it is specified
that, unless otherwise provided for by national regulations, offlabel use of medication should …

The considerable progress made in the field of cancer treatment has led to a dramatic
improvement in the prognosis of patients with cancer. However, toxicities resulting from …

Aims The national incidence, risk factors, and associated mortality of atrial fibrillation (AF) in
breast cancer patients are unknown. Methods and results Using the Surveillance …

Background Drug development for atrial fibrillation (AF) has failed to yield new approved
compounds. We sought to identify and prioritise potential druggable targets with support …

Cardio-oncology has grown rapidly worldwide as an emerging interdisciplinary discipline
over the past decade. In the present bibliometric review, we employed VOSviewer and …

Despite improvements in cancer survival, cancer therapy–related cardiovascular toxicity has
risen to become a prominent clinical challenge. This has led to the growth of the burgeoning …

FMS-like tyrosine kinase 3 (FLT3) mutations occur in almost 30% of acute myeloid leukemia
(AML) patients. Despite the initial clinical efficacy of FLT3 inhibitors, many treated AML …

Background The incidence of atrial fibrillation (AF) associated with anticancer drugs in
cancer patients remains incompletely defined. Objectives The primary outcome was the …